Meeder Asset Management’s Alder Biopharmaceuticals ALDR Stock Holding History

Meeder Asset Management’s Portfolio ALDR Stock Details ALDR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-73	Closed	-$1K	–	1874
2017 Q3	$1K	Sell	73 -74	-50%	-$772	﹤0.01%	1593
2017 Q2	$2K	Sell	147 -103	-41%	-$1.9K	﹤0.01%	1467
2017 Q1	$5K	Buy	+250	New	+$5.53K	﹤0.01%	1124
2016 Q3	–	Sell	-2,665	Closed	-$67K	–	1029
2016 Q2	$67K	Sell	2,665 -1,942	-42%	-$52.5K	0.01%	696
2016 Q1	$113K	Hold	4,607	–	–	0.01%	682
2015 Q4	$152K	Hold	4,607	–	–	0.01%	567
2015 Q3	$151K	Buy	+4,607	New	+$196K	0.01%	541

Other funds holding ALDR

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Meeder Asset Management's ALDR Position: Q4 2017 in Review

Meeder Asset Management sold out of Alder Biopharmaceuticals (ALDR) in Q4 2017, closing a stake of 73 shares — an estimated $1K sold.

Meeder Asset Management first reported a position in ALDR in Q3 2015 and held it in 7 quarters. The position peaked at $152K in Q4 2015. 140 funds tracked by Wall St. Rank hold ALDR as of Q4 2017.

Meeder Asset Management reported no remaining Alder Biopharmaceuticals position as of Q4 2017 after selling out during the quarter.
Meeder Asset Management sold 73 Alder Biopharmaceuticals shares in Q4 2017, an estimated $1K.
Meeder Asset Management first reported a position in Alder Biopharmaceuticals in Q3 2015 and held it in 7 quarters.
Meeder Asset Management's Alder Biopharmaceuticals position peaked at $152K in Q4 2015.
140 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2017.

Based on Meeder Asset Management's 13F filing for Q4 2017, filed 2 Feb 2018.